$ANGO 8-K SEC Filings

Filed On	Filing
08 Oct 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability
08 Oct 2026	8-K: Entry into a Material Definitive Agreement; Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers This Employment Agreement (the “Agreement”) is entered into by and between AngioDynamics, Inc, a Delaware corporation (the “Company”) and Eric Honroth (“Executive”) (together, the “Parties” and individually, a “Party”).
14 Jul 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
23 Apr 2026	8-K: Other Events
02 Apr 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
03 Feb 2026	8-K: Departure/Election of Directors or Officers; Compensation
14 Jan 2026	8-K: Regulation FD Disclosure
06 Jan 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
12 Nov 2025	8-K: Submission of Matters to a Vote of Security Holders
02 Oct 2025	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
15 Jul 2025	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
28 May 2025	8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
02 Apr 2025	8-K: Regulation FD Disclosure
02 Apr 2025	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
16 Jan 2025	8-K: Regulation FD Disclosure
08 Jan 2025	8-K: Regulation FD Disclosure
08 Jan 2025	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
15 Nov 2024	8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
03 Oct 2024	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
16 Jul 2024	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Comments